Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 8/20 | 0.57 |
| ▸ | HSD17B2 | P37059 | 8/20 | 0.57 |
| ▸ | FASN | P49327 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.56 |
| ▸ | CLK1 | P49759 | 1/20 | 0.56 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | HSD17B14 | Q9BPX1 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17235856 | 0.85 | CES2 (0.53) | HSD17B1HSD17B2KDM4EPARP1MEN1 | |
| SCHEMBL1129171 | 0.84 | ATM (0.55) | HSD17B14MEN1NPC1RAB9AKMT2A | |
| SCHEMBL3468572 | 0.84 | HTT (0.56) | HSD17B1HSD17B2CA2HSD17B14MEN1 | |
| SCHEMBL809540 | 0.80 | FASN (0.76) | HSD17B1HSD17B2FASNDYRK1ACLK1 | |
| SCHEMBL29699163 | 0.80 | FASN (0.76) | HSD17B1HSD17B2FASNDYRK1ACLK1 | |
| SCHEMBL17235834 | 0.79 | LTA4H (0.50) | KDM4ECA1CA2NPC1RAB9A | |
| SCHEMBL9468468 | 0.79 | HSD17B1 (0.64) | HSD17B1HSD17B2FASNDYRK1ACLK1 | |
| SCHEMBL26988699 | 0.79 | CLK1 (0.62) | HSD17B1HSD17B2FASNDYRK1ACLK1 | |
| SCHEMBL3467828 | 0.78 | CES2 (0.54) | PARP1STSMEN1NPC1RAB9A | |
| SCHEMBL7886475 | 0.77 | FASN (0.61) | HSD17B1HSD17B2FASNDYRK1ACLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799828-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | GLAXOSMITHKLINE LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090253659-A1 | Cycloalkylidene Compounds As Modulators of Estrogen Receptor | GLAXOSMITHKLINE LLC | 2009-10-08 | — | — | US | disclosed |
| US-7569601-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-7560589-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070213348-A1 | Chemical Compounds | BRITTON JONATHAN E | 2007-09-13 | — | — | US | disclosed |
| US-20070155839-A1 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| EP-1667955-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF THE ESTROGEN RECEPTOR | SmithKline Beecham Corporation (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005012220-A9 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORP (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005012220-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155839-A1 | Cycloalkylidene compounds as modulators of estrogen receptor | ESR2, GPER1, ESRRG | HSD17B1 155/4885HSD17B2 108/4885FASN 1716/4885 |
| US-20090253659-A1 | Cycloalkylidene Compounds As Modulators of Estrogen Receptor | ESR2, GPER1, ESRRG | HSD17B1 155/4885HSD17B2 108/4885FASN 1716/4885 |
| US-20070213348-A1 | Chemical Compounds | GPER1, ESR2, ESR1 | HSD17B1 147/4885HSD17B2 83/4885FASN 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.